Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice

Journal of Clinical Investigation

Volumn 119, Issue 5, 2009, Pages 1216-1229

  Qing, Jing ^a   Du, Xiangnan ^a   Chen, Yongmei ^a   Chan, Pamela ^a   Li, Hao ^a   Wu, Ping ^a   Marsters, Scot ^a   Stawicki, Scott ^a   Tien, Janet ^a   Totpal, Klara ^a   Ross, Sarajane ^a   Stinson, Susanna ^a   Dornan, David ^a   French, Dorothy ^a   Wang, Qian Rena ^a   Stephan, Jean Philippe ^a   Wu, Yan ^a   Wiesmann, Christian ^a   Ashkenazi, Avi ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; DISULFIDE; EPITOPE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 3 ANTIBODY; LIGAND; MONOCLONAL ANTIBODY; MUTANT PROTEIN; UNCLASSIFIED DRUG; FGFR3 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; FRS2 PROTEIN, HUMAN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTALLOGRAPHY; DIMERIZATION; DRUG CONFORMATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; KNOCKOUT GENE; LIGAND BINDING; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; XENOGRAFT; ANIMAL; ANTIGEN ANTIBODY COMPLEX; BLADDER TUMOR; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENE TRANSLOCATION; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN CONFORMATION; RNA INTERFERENCE; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGEN-ANTIBODY COMPLEX; CELL LINE, TUMOR; CELL PROLIFERATION; EPITOPES; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MEMBRANE PROTEINS; MICE; MICE, NUDE; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, MOLECULAR; MULTIPLE MYELOMA; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSLOCATION, GENETIC; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66349135677     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI38017     Document Type: Article

References (49)

1. Eswarakumar, V.P., Lax, I., and Schlessinger, J. 2005. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 16:139-149.
2. L'Hote, C.G., and Knowles, M.A. 2005. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp. Cell Res. 304:417-431.
3. Dailey, L., Ambrosetti, D., Mansukhani, A., and Basilico, C. 2005. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev. 16:233-247.
4. Mohammadi, M., Olsen, S.K., and Ibrahimi, O.A. 2005. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 16:107-137.
5. Grose, R., and Dickson, C. 2005. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev. 16:179-186.
6. Chang, H., et al. 2005. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood. 106:353-355.
7. Chesi, M., et al. 1997. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet. 16:260-264.
8. Fonseca, R., et al. 2003. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 101:4569-4575.
9. Moreau, P., et al. 2002. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 100:1579-1583.
10. Pollett, J.B., Trudel, S., Stern, D., Li, Z.H., and Stewart, A.K. 2002. Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance. Blood. 100:3819-3821.
11. Bernard-Pierrot, I., et al. 2006. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis. 27:740-747.
12. Agazie, Y.M., Movilla, N., Ischenko, I., and Hayman, M.J. 2003. The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3. Oncogene. 22:6909-6918.
13. Ronchetti, D., et al. 2001. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene 20:3553-3562.
14. Chesi, M., et al. 2001. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood. 97:729-736.
15. Plowright, E.E., et al. 2000. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood. 95:992-998.
16. Chen, J., et al. 2005. Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation. Blood. 106:328-337.
17. Li, Z., et al. 2001. The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood. 97:2413-2419.
18. Trudel, S., et al. 2004. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood. 103:3521-3528.
19. Trudel, S., et al. 2005. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood. 105:2941-2948.
20. Chen, J., et al. 2005. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene. 24:8259-8267.
21. Paterson, J.L., et al. 2004. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br. J. Haematol. 124:595-603.
22. Grand, E.K., Chase, A.J., Heath, C., Rahemtulla, A., and Cross, N.C. 2004. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia. 18:962-966.
23. Gomez-Roman, J.J., et al. 2005. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin. Cancer Res. 11:459-465.
24. Tomlinson, D.C., Baldo, O., Harnden, P., and Knowles, M.A. 2007. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J. Pathol. 213:91-98.
25. van Rhijn, B.W., Montironi, R., Zwarthoff, E.C., Jobsis, A.C., and van der Kwast, T.H. 2002. Frequent FGFR3 mutations in urothelial papilloma. J. Pathol. 198:245-251.
26. Tomlinson, D.C., Hurst, C.D., and Knowles, M.A. 2007. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene. 26:5889-5899.
27. Martinez-Torrecuadrada, J., et al. 2005. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin. Cancer Res. 11:6280-6290.
28. Martinez-Torrecuadrada, J.L., et al. 2008. Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis. Mol. Cancer Ther. 7:862-873.
29. Ornitz, D.M., and Leder, P. 1992. Ligand specificity and heparin dependence of fibroblast growth factor receptors 1 and 3. J. Biol. Chem. 267:16305-16311.
30. d'Avis, P.Y., et al. 1998. Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. Cell Growth Differ. 9:71-78.
31. Adar, R., Monsonego-Ornan, E., David, P., and Yayon, A. 2002. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization. J. Bone Miner. Res. 17:860-868.
32. Knowles, M.A. 2008. Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors. Future Oncol. 4:71-83.
33. Naski, M.C., Wang, Q., Xu, J., and Ornitz, D.M. 1996. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat. Genet. 13:233-237.
34. Plotnikov, A.N., Schlessinger, J., Hubbard, S.R., and Mohammadi, M. 1999. Structural basis for FGF receptor dimerization and activation. Cell. 98:641-650.
35. Olsen, S.K., et al. 2004. Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc. Natl. Acad. Sci. U. S. A. 101:935-940.
36. Jebar, A.H., et al. 2005. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene. 24:5218-5225.
37. Ellman, G.L. 1959. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82:70-77.
38. Adams, G.P., and Weiner, L.M. 2005. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23:1147-1157.
39. Gong, Q., et al. 2005. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174:817-826.
40. Cappellen, D., et al. 1999. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet. 23:18-20.
41. Qiu, W.H., et al. 2005. Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma. World J. Gastroenterol. 11:5266-5272.
42. Cortese, R., Hartmann, O., Berlin, K., and Eckhardt, F. 2008. Correlative gene expression and DNA methylation profiling in lung development nominate new biomarkers in lung cancer. Int. J. Biochem. Cell Biol. 40:1494-1508.
43. Woenckhaus, M., et al. 2006. Smoking and cancer-related gene expression in bronchial epithelium and non-small-cell lung cancers. J. Pathol. 210:192-204.
44. Xin, X., et al. 2006. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin. Cancer Res. 12:4908-4915.
45. Davies, H., et al. 2002. Mutations of the BRAF gene in human cancer. Nature. 417:949-954.
46. Trudel, S., et al. 2006. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood. 107:4039-4046.
47. Gozlan, H., and Ben-Ari, Y. 1995. NMDA receptor redox sites: are they targets for selective neuronal protection? Trends Pharmacol. Sci. 16:368-374.
48. Hudziak, R.M., et al. 1989. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9:1165-1172.
49. Masui, H., et al. 1984. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 44:1002-1007.